We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-14.83%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.16B
AUM Growth
-$1.15B
Cap. Flow
+$52.2M
Cap. Flow %
1.01%
Top 10 Hldgs %
40.75%
Holding
232
New
16
Increased
80
Reduced
52
Closed
17

Top Buys

Rank Stock Value
1
BDTX icon
Black Diamond Therapeutics
BDTX
+$40.5M
2
FATE icon
Fate Therapeutics
FATE
+$37.4M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$29.7M
4
ESPR
Esperion Therapeutics
ESPR
+$27.1M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$25.4M

Top Sells

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$63.8M
2
BMY icon
Bristol-Myers Squibb
BMY
+$54M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$26.7M
4
MRNA icon
Moderna
MRNA
+$22.7M
5
ALGN icon
Align Technology
ALGN
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.76%
2 Technology 0.56%
3 Industrials 0.54%
4 Communication Services 0.17%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
101
Guardant Health
GH
$20.7B
$7.33M 0.14%
105,294
-4,842
-4% -$372K
ONC
102
BeOne Medicines Ltd
ONC
$32.4B
$7.2M 0.14%
58,500
+11,644
+25% +$1.82M
CDTX
103
DELISTED
Cidara Therapeutics
CDTX
$7M 0.14%
141,125
+26,361
+23% +$1.58M
COO icon
104
Cooper Companies
COO
$14B
$6.99M 0.14%
101,380
-64,760
-39% -$5.27M
HCAT icon
105
Health Catalyst
HCAT
$166M
$6.62M 0.13%
253,000
+28,492
+13% +$871K
XENT
106
DELISTED
Intersect ENT, Inc
XENT
$6.46M 0.13%
545,022
-25,880
-5% -$574K
INGN icon
107
Inogen
INGN
$178M
$6.38M 0.12%
123,395
-14,392
-10% -$691K
OXFD
108
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$6.13M 0.12%
662,315
+24,343
+4% +$340K
SILK
109
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$6.13M 0.12%
194,583
+10,687
+6% +$428K
BMRN icon
110
BioMarin Pharmaceuticals
BMRN
$11.5B
$6.09M 0.12%
72,100
+4,900
+7% +$422K
TXG icon
111
10x Genomics
TXG
$5.55B
$5.85M 0.11%
93,847
-35,280
-27% -$2.75M
XRAY icon
112
Dentsply Sirona
XRAY
$2.81B
$4.97M 0.1%
128,038
-38,001
-23% -$1.94M
HZNP
113
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.92M 0.1%
166,000
-149,700
-47% -$5.06M
SGEN
114
DELISTED
Seagen Inc. Common Stock
SGEN
$4.78M 0.09%
41,400
+4,000
+11% +$443K
AXNX
115
DELISTED
Axonics, Inc. Common Stock
AXNX
$4.56M 0.09%
+179,333
New +$5.33M
ONEM
116
DELISTED
1Life Healthcare
ONEM
$4.54M 0.09%
+250,000
New +$5.48M
AVTR icon
117
Avantor
AVTR
$7.56B
$3.93M 0.08%
314,566
– –
QGEN icon
118
Qiagen
QGEN
$8.49B
$3.85M 0.07%
87,327
-64,360
-42% -$2.51M
BMY.RT
119
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$3.1M 0.06%
816,600
– –
PFE icon
120
Pfizer
PFE
$143B
$2.94M 0.06%
94,860
+31,620
+50% +$1.08M
PTCT icon
121
PTC Therapeutics
PTCT
$6.52B
$2.91M 0.06%
65,200
+9,100
+16% +$458K
UBER icon
122
Uber
UBER
$147B
$2.79M 0.05%
+100,000
New +$3.29M
PANW icon
123
Palo Alto Networks
PANW
$292B
$2.79M 0.05%
+102,000
New +$3.56M
TEVA icon
124
Teva Pharmaceuticals
TEVA
$37.3B
$2.72M 0.05%
303,000
+37,000
+14% +$379K
BIIB icon
125
Biogen
BIIB
$30.4B
$2.69M 0.05%
8,500
+8,000
+1,600% +$2.43M
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2020 Portfolio in Review

As of Q1 2020, Bellevue Group held 232 positions worth $5.16B, down 18% from $6.31B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q1 2020 filing shows 16 new, 80 increased, 52 reduced and 17 closed positions. Its largest new stake was Black Diamond Therapeutics: 1,330,000 shares worth $33.2M. The largest sale was Teladoc Health, an estimated $63.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Technology and Industrials.

  • Bellevue Group's largest Q1 2020 buy was Black Diamond Therapeutics: 1,330,000 shares worth $33.2M.
  • Bellevue Group added most to Fate Therapeutics in Q1 2020, an estimated $37.4M increase.
  • Bellevue Group's biggest Q1 2020 reduction was Teladoc Health, cutting an estimated $63.8M.
  • Bellevue Group fully exited Wright Medical Group Inc in Q1 2020, selling an estimated $17.1M.
  • Bellevue Group's ten largest holdings make up 41% of its $5.16B portfolio in Q1 2020.
  • Bellevue Group opened 16 new positions and closed 17 in Q1 2020.
  • Bellevue Group's portfolio value fell 18% quarter-over-quarter to $5.16B.

Based on Bellevue Group's 13F filing for Q1 2020, filed 14 May 2020.